Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.

Antibodies, Viral COVID-19 / prevention & control Humans Immunity Immunoglobulin G Renal Dialysis SARS-CoV-2 Vaccination Vaccines, Synthetic mRNA Vaccines
COVID-19 SARS-CoV-2 dialysis immunology mRNA vaccine memory B cells

Journal

Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570

Informations de publication

Date de publication:
07 2022
Historique:
received: 19 01 2022
accepted: 16 05 2022
pubmed: 29 6 2022
medline: 12 7 2022
entrez: 28 6 2022
Statut: ppublish

Résumé

After two doses of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients on dialysis show a defective humoral response, but a third dose could increase anti-SARS-CoV-2 spike IgG titers. Responses could be different in virus-naive and SARS-CoV-2-recovered patients on dialysis. However, characterization of memory B cell response after three doses is lacking. We evaluated the dynamics of antireceptor binding domain IgG titers and antireceptor binding domain memory B cells until 6 months after two and three doses (administered within 6 months after the second dose) of mRNA vaccine in SARS-CoV-2-recovered and virus-naive dialysis populations. Results were analyzed by ordinary one-way ANOVA, the Kruskal-Wallis test, or the Wilcoxon matched-pairs test as appropriate. In total, 108 individuals (59 patients on dialysis and 49 controls) were included. In virus-naive patients on dialysis, antireceptor binding domain IgG response was quantitatively lower after two doses compared with healthy controls, but IgG titers increased by three-fold after three doses ( The third dose of mRNA vaccine given within 6 months after the second dose boosts serologic and memory response in virus-naive patients but not in SARS-CoV-2-recovered patients on dialysis. COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells (MEMO-COV2), NCT04402892.

Sections du résumé

BACKGROUND AND OBJECTIVES
After two doses of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients on dialysis show a defective humoral response, but a third dose could increase anti-SARS-CoV-2 spike IgG titers. Responses could be different in virus-naive and SARS-CoV-2-recovered patients on dialysis. However, characterization of memory B cell response after three doses is lacking.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS
We evaluated the dynamics of antireceptor binding domain IgG titers and antireceptor binding domain memory B cells until 6 months after two and three doses (administered within 6 months after the second dose) of mRNA vaccine in SARS-CoV-2-recovered and virus-naive dialysis populations. Results were analyzed by ordinary one-way ANOVA, the Kruskal-Wallis test, or the Wilcoxon matched-pairs test as appropriate.
RESULTS
In total, 108 individuals (59 patients on dialysis and 49 controls) were included. In virus-naive patients on dialysis, antireceptor binding domain IgG response was quantitatively lower after two doses compared with healthy controls, but IgG titers increased by three-fold after three doses (
CONCLUSIONS
The third dose of mRNA vaccine given within 6 months after the second dose boosts serologic and memory response in virus-naive patients but not in SARS-CoV-2-recovered patients on dialysis.
CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER
COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells (MEMO-COV2), NCT04402892.

Identifiants

DOI: 10.2215/CJN.00830122 PMID: 35764393 PMC: PMC9269639
pubmed: 35764393
pii: 01277230-202207000-00012
doi: 10.2215/CJN.00830122
pmc: PMC9269639
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Vaccines, Synthetic 0
mRNA Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT04402892']

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1008-1016

Investigateurs

Vincent Audard (V)
Boutheina Bentaarit (B)
Anna Boueilh (A)
Sébastien Gallien (S)
Philippe Grimbert (P)
Sophie Hue (S)
Nizar Joher (N)
Narindra Jouan (N)
Larbi Lamriben (L)
Jean-Daniel Lelièvre (JD)
Raphaël Lepeule (R)
Matthieu Mahévas (M)
Marie Matignon (M)
Giovanna Melica (G)
Julie Oniszczuk (J)
Jean-Michel Pawlotsky (JM)
Thomas Stehlé (T)
William Vindrios (W)
Charlotte Wemmert (C)

Informations de copyright

Copyright © 2022 by the American Society of Nephrology.

Références

Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, Collart F, Hemmelder MH, Ambühl P, Kerschbaum J, Legeai C, Del Pino Y Pino MD, Mircescu G, Mazzoleni L, Hoekstra T, Winzeler R, Mayer G, Stel VS, Wanner C, Zoccali C, Massy ZA: Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 98: 1540–1548, 2020
Couchoud C, Bayer F, Ayav C, Béchade C, Brunet P, Chantrel F, Frimat L, Galland R, Hourmant M, Laurain E, Lobbedez T, Mercadal L, Moranne O; French REIN registry: Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. Kidney Int 98: 1519–1529, 2020
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B: Factors associated with COVID-19-related death using OpenSAFELY. Nature 584: 430–436, 2020
De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS; NBVN Kidney Registry Group: Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: A regionwide registry study. J Am Soc Nephrol 32: 385–396, 2021
Clarke C, Prendecki M, Dhutia A, Ali MA, Sajjad H, Shivakumar O, Lightstone L, Kelleher P, Pickering MC, Thomas D, Charif R, Griffith M, McAdoo SP, Willicombe M: High prevalence of asymptomatic COVID-19 infection in hemodialysis patients detected using serologic screening. J Am Soc Nephrol 31: 1969–1975, 2020
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD: BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384: 1412–1423, 2021
Ikizler TA, Coates PT, Rovin BH, Ronco P: Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int 99: 1275–1279, 2021
Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E, Chalencon E, Mathias V, Ovize A, Cart-Tanneur E, Bouz C, Pellegrina L, Morelon E, Fouque D, Juillard L, Thaunat O: The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int 100: 928–936, 2021
Van Praet J, Reynders M, De Bacquer D, Viaene L, Schoutteten M, Caluwé R, Doubel P, Heylen L, De Bel AV, Van Vlem B, Steensels D, De Vriese AS: Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: A multicenter observational study. J Am Soc Nephrol 32: 3208–3220, 2021
Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, Faulhaber-Walter R, Schewe J, Martin H, Schirutschke H, Barnett K, Hüther J, Müller P, Langer T, Pluntke T, Anding-Rost K, Meistring F, Stehr T, Pietzonka A, Escher K, Cerny S, Rothe H, Pistrosch F, Seidel H, Paliege A, Beige J, Bast I, Steglich A, Gembardt F, Kessel F, Kröger H, Arndt P, Sradnick J, Frank K, Klimova A, Mauer R, Grählert X, Anft M, Blazquez-Navarro A, Westhoff TH, Stervbo U, Tonn T, Babel N, Hugo C: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur 9: 100178, 2021
Sibbel S, McKeon K, Luo J, Wendt K, Walker AG, Kelley T, Lazar R, Zywno ML, Connaire JJ, Tentori F, Young A, Brunelli SM: Real-world effectiveness and immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients on hemodialysis. J Am Soc Nephrol 33: 49–57, 2022
Espi M, Charmetant X, Barba T, Mathieu C, Pelletier C, Koppe L, Chalencon E, Kalbacher E, Mathias V, Ovize A, Cart-Tanneur E, Bouz C, Pellegrina L, Morelon E, Juillard L, Fouque D, Couchoud C, Thaunat O; REIN Registry: A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. Kidney Int 100: 928–936, 2021
Cho A, Muecksch F, Schaefer-Babajew D, Wang Z, Finkin S, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC: Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature 600: 517–522, 2021
Sokal A, Barba-Spaeth G, Fernández I, Broketa M, Azzaoui I, de La Selle A, Vandenberghe A, Fourati S, Roeser A, Meola A, Bouvier-Alias M, Crickx E, Languille L, Michel M, Godeau B, Gallien S, Melica G, Nguyen Y, Zarrouk V, Canoui-Poitrine F, Pirenne F, Mégret J, Pawlotsky JM, Fillatreau S, Bruhns P, Rey FA, Weill JC, Reynaud CA, Chappert P, Mahévas M: mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54: 2893–2907.e5, 2021
Rincon-Arevalo H, Choi M, Stefanski AL, Halleck F, Weber U, Szelinski F, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, Kotsch K, Potekhin A, Chen Y, Burmester GR, Eckardt KU, Guerra GM, Durek P, Heinrich F, Ferreira-Gomes M, Radbruch A, Budde K, Lino AC, Mashreghi MF, Schrezenmeier E, Dörner T: Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol 6: eabj1031, 2021
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3: 1526–1533, 2008
Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C: Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int 100: 702–704, 2021
Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B, Del Bello A, Marion O, Faguer S, Izopet J, Kamar N: High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant 36: 1704–1709, 2021
Stervbo U, Blazquez-Navarro A, Blanco EV, Safi L, Meister TL, Paniskaki K, Stockhausen M, Marheinecke C, Zimmer G, Wellenkötter J, Giglio T, Arora P, Pöhlmann S, Hoffmann M, Seibert FS, Pfaender S, Roch T, Westhoff TH, Cinkilic O, Babel N: Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease. Kidney Int 100: 1335–1337, 2021
Anand S, Montez-Rath M, Han J, Cadden L, Hunsader P, Kerschmann R, Beyer P, Boyd SD, Garcia P, Dittrich M, Block GA, Parsonnet J, Chertow GM: Estimated SARS-CoV-2 seroprevalence in US patients receiving dialysis 1 year after the beginning of the COVID-19 pandemic. JAMA Netw Open 4: e2116572, 2021
Sokal A, Barba-Spaeth G, Fernández I, Broketa M, Azzaoui I, de La Selle A, Vandenberghe A, Fourati S, Roeser A, Meola A, Bouvier-Alias M, Crickx E, Languille L, Michel M, Godeau B, Gallien S, Melica G, Nguyen Y, Zarrouk V, Canoui-Poitrine F, Pirenne F, Mégret J, Pawlotsky J-M, Fillatreau S, Bruhns P, Rey FA, Weill J-C, Reynaud C-A, Chappert P, Mahévas M: mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54: 2893–2907, 2021
Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H, Budde K, Storz E, Proß V, Bergmann Y, Thole LM, Tizian C, Hölsken O, Diefenbach A, Schrezenmeier H, Jahrsdörfer B, Zemojtel T, Jechow K, Conrad C, Lukassen S, Stauch D, Lachmann N, Choi M, Halleck F, Kotsch K: Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest 131: 150175, 2021
Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, Gouma S, Kuri-Cervantes L, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Baxter AE, Oldridge DA, Giles JR, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Drapeau EM, Dougherty J, Long S, D’Andrea K, Hamilton JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, Frank I, Betts MR, Vella LA, Grifoni A, Weiskopf D, Sette A, Hensley SE, Davenport MP, Bates P, Luning Prak ET, Greenplate AR, Wherry EJ; UPenn COVID Processing Unit: mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374: abm0829, 2021
Sokal A, Broketa M, Barba-Spaeth G, Meola A, Fernández I, Fourati S, Azzaoui I, La Selle A, Vandenberghe A, Roeser A, Bouvier-Alias M, Crickx E, Languille L, Michel M, Godeau B, Gallien S, Melica G, Nguyen Y, Zarrouk V, Canoui-Poitrine F, Noizat-Pirenne F, Megret J, Pawlotsky J-M, Fillatreau S, Simon-Lorière E, Weill J-C, Reynaud C-A, Rey FA, Bruhns P, Chappert P, Mahévas M: Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant [published online ahead of print April 7, 2022]. Immunity 10.1016/j.immuni.2022.04.002
doi: 10.1016/j.immuni.2022.04.002
Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, Kurth F, Sander LE, Klein F: mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med 28: 477–480, 2022
Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, Feldman J, Roederer AL, Gregory DJ, Poznansky MC, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB: mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185: 457–466.e4, 2022

Auteurs

Philippe Attias (P)

Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France.

Imane Azzaoui (I)

Department of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 2, Transfusion and pathologies of the red blood cell, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.

Khalil El Karoui (K)

Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.

Andréa de La Selle (A)

Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France.
ORCID: 0000-0002-9098-0107

Aurélien Sokal (A)

Department of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 2, Transfusion and pathologies of the red blood cell, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.

Pascal Chappert (P)

Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France.
Institut Pasteur, Unité de Virologie Structurale, Centre National de Recherche Scientifique Unité Mixte de Recherche 3569, Paris, France.

Philippe Grimbert (P)

Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.

Ignacio Fernandez (I)

Institut Pasteur, Unité de Virologie Structurale, Centre National de Recherche Scientifique Unité Mixte de Recherche 3569, Paris, France.

Magali Bouvier (M)

Département de Virologie, Bactériologie, Hygiène et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 18, Viruses, Hepatology, Cancer, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.
ORCID: 0000-0003-1590-5980

Chloé Samson (C)

Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.

Djamal Dahmane (D)

Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.

Philippe Rieu (P)

Department of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France.

Patrice Nizard (P)

Ana Laboratoires, Sarcelles, France.

Slim Fourati (S)

Département de Virologie, Bactériologie, Hygiène et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 18, Viruses, Hepatology, Cancer, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.

Hamza Sakhi (H)

Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.
ORCID: 0000-0003-4977-2661

Matthieu Mahévas (M)

Department of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France.
Institut National de la Santé et de la Recherche Médical U955, Équipe 2, Transfusion and pathologies of the red blood cell, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.
Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Thérapeutique › Détoxication par sorption › Dialyse rénale › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Immune Responses after a Third Dose of mRNA...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Immune Responses after a Third Dose of mRNA...